A detailed history of Northern Trust Corp transactions in Uni Qure N.V. stock. As of the latest transaction made, Northern Trust Corp holds 93,668 shares of QURE stock, worth $1.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
93,668
Previous 93,928 0.28%
Holding current value
$1.63 Million
Previous $420,000 9.76%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.78 - $10.12 $982 - $2,631
-260 Reduced 0.28%
93,668 $461,000
Q2 2024

Aug 14, 2024

BUY
$4.39 - $5.43 $39,615 - $49,000
9,024 Added 10.63%
93,928 $420,000
Q1 2024

May 14, 2024

SELL
$4.82 - $6.93 $10,753 - $15,460
-2,231 Reduced 2.56%
84,904 $441,000
Q4 2023

Feb 13, 2024

SELL
$5.63 - $8.27 $196,931 - $289,276
-34,979 Reduced 28.64%
87,135 $589,000
Q3 2023

Nov 13, 2023

SELL
$6.71 - $11.83 $266,541 - $469,923
-39,723 Reduced 24.55%
122,114 $819,000
Q2 2023

Aug 11, 2023

SELL
$11.12 - $22.2 $42,222 - $84,293
-3,797 Reduced 2.29%
161,837 $1.85 Million
Q1 2023

May 15, 2023

BUY
$18.7 - $23.07 $46,899 - $57,859
2,508 Added 1.54%
165,634 $3.34 Million
Q4 2022

Feb 13, 2023

BUY
$18.12 - $27.32 $74,980 - $113,050
4,138 Added 2.6%
163,126 $3.7 Million
Q3 2022

Nov 14, 2022

BUY
$16.98 - $25.54 $335,456 - $504,568
19,756 Added 14.19%
158,988 $2.98 Million
Q2 2022

Aug 12, 2022

BUY
$13.15 - $20.45 $162,310 - $252,414
12,343 Added 9.73%
139,232 $2.6 Million
Q1 2022

May 13, 2022

SELL
$14.54 - $21.5 $77,207 - $114,165
-5,310 Reduced 4.02%
126,889 $2.29 Million
Q4 2021

Feb 08, 2022

BUY
$20.24 - $36.01 $1,882 - $3,348
93 Added 0.07%
132,199 $2.74 Million
Q3 2021

Nov 15, 2021

BUY
$26.01 - $38.22 $998,393 - $1.47 Million
38,385 Added 40.96%
132,106 $4.23 Million
Q2 2021

Aug 13, 2021

BUY
$29.97 - $37.17 $110,199 - $136,674
3,677 Added 4.08%
93,721 $2.89 Million
Q1 2021

May 12, 2021

BUY
$29.24 - $42.03 $305,148 - $438,625
10,436 Added 13.11%
90,044 $3.03 Million
Q4 2020

Feb 11, 2021

SELL
$35.35 - $50.67 $85,158 - $122,064
-2,409 Reduced 2.94%
79,608 $2.88 Million
Q3 2020

Nov 16, 2020

BUY
$35.98 - $47.66 $2.5 Million - $3.31 Million
69,500 Added 555.24%
82,017 $3.02 Million
Q2 2020

Aug 14, 2020

SELL
$45.06 - $67.74 $1.66 Million - $2.5 Million
-36,858 Reduced 74.65%
12,517 $564,000
Q1 2020

May 14, 2020

BUY
$40.01 - $73.97 $68,697 - $127,006
1,717 Added 3.6%
49,375 $2.34 Million
Q4 2019

Feb 14, 2020

BUY
$37.13 - $74.62 $101,513 - $204,011
2,734 Added 6.09%
47,658 $3.42 Million
Q3 2019

Nov 13, 2019

BUY
$39.36 - $76.8 $49,514 - $96,614
1,258 Added 2.88%
44,924 $1.77 Million
Q2 2019

Aug 13, 2019

BUY
$52.76 - $82.19 $154,639 - $240,898
2,931 Added 7.2%
43,666 $3.41 Million
Q1 2019

May 13, 2019

BUY
$27.39 - $68.41 $209,506 - $523,268
7,649 Added 23.12%
40,735 $2.43 Million
Q4 2018

Feb 12, 2019

BUY
$22.8 - $33.93 $18,171 - $27,042
797 Added 2.47%
33,086 $954,000
Q3 2018

Nov 14, 2018

BUY
$29.75 - $43.08 $486,977 - $705,176
16,369 Added 102.82%
32,289 $1.18 Million
Q2 2018

Aug 14, 2018

BUY
$21.96 - $39.94 $349,603 - $635,844
15,920 New
15,920 $602,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $811M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.